Hepatitis C virus and interferon resistance (Q34117485)

31 July 2017

1 reference

title

Hepatitis C virus and interferon resistance (English)

1 reference

31 July 2017

1 reference

1 reference

D R Taylor

1

1 reference

PubMed ID

11137047

31 July 2017

S T Shi

series ordinal

2

1 reference

PubMed ID

11137047

31 July 2017

M M Lai

series ordinal

3

1 reference

31 July 2017

1 November 2000

1 reference

31 July 2017

Microbes and Infection

1 reference

31 July 2017

2

1 reference

31 July 2017

14

1 reference

31 July 2017

1743-1756

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

31 July 2017

1 reference

7 January 2021

Infection of peripheral mononuclear blood cells by hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Testing for hepatitis C virus sequences in peripheral blood mononuclear cells of patients with chronic hepatitis C in the absence of serum hepatitis C virus RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Management of hepatitis C: current and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Transcription of interferon-stimulated genes is induced by adenovirus particles but is suppressed by E1A gene products

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Inhibition of the cellular response to interferons by products of the adenovirus type 5 E1A oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-induced eIF-2 alpha kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Poxvirus-encoded soluble cytokine receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Antiviral actions of interferon interferon-regulated cellular proteins and their surprisingly selective antiviral activities

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Cytokines and STATs: how can signals achieve specificity?

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Marked sequence diversity in the putative envelope proteins of hepatitis C viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Hypervariable regions in the putative glycoprotein of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

The hypervariable region of the HCV genome changes sequentially during the progression of acute HCV infection to chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Virus isolate-specific antibodies against hypervariable region 1 of the hepatitis C virus second envelope protein, gp70.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

High prevalence of hypervariable region 1-specific and -cross-reactive CD4(+) T cells in HCV-infected individuals responsive to IFN-alpha treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Genotype, slow decrease in virus titer during interferon treatment and high degree of sequence variability of hypervariable region are indicative of poor response to interferon treatment in patients with chronic hepatitis type C.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A-associated kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Identification of the major phosphorylation site of the hepatitis C virus H strain NS5A protein as serine 2321

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Hepatitis C virus quasispecies populations during chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

The interferon sensitivity determining region: all hepatitis C virus isolates are not the same

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Why is the interferon sensitivity-determining region (ISDR) system useful in Japan?

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

The amino terminal deletion mutants of hepatitis C virus nonstructural protein NS5A function as transcriptional activators in yeast

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Genotypic subtyping of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Clearance of serum hepatitis C virus RNA after interferon therapy in relation to virus genotype.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Factors predictive of a beneficial response to therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

The double-stranded RNA-dependent protein kinase PKR: structure and function

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Mutants of the RNA-dependent protein kinase (PKR) lacking double-stranded RNA binding domain I can act as transdominant inhibitors and induce malignant transformation

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Inhibitory role of the host apoptogenic gene PKR in the establishment of persistent infection by encephalomyocarditis virus in U937 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Autophosphorylation sites participate in the activation of the double-stranded-RNA-activated protein kinase PKR

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Adenovirus inhibition of cellular protein synthesis is prevented by the drug 2-aminopurine

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

A mechanism for the control of protein synthesis by adenovirus VA RNAI.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

The war against the interferon-induced dsRNA-activated protein kinase: can viruses win?

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

PKR: a new name and new roles.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Inhibition of double-stranded RNA-dependent protein kinase PKR by vaccinia virus E3: role of complex formation and the E3 N-terminal domain

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Regulation of the interferon-induced PKR: can viruses cope?

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

2′,5′ oligoadenyIate synthetase activity in peripheral blood mononuclear cells and serum during interferon treatment of chronic non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Activity of the interferon-induced 2',5'-oligoadenylate synthetase in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

HCV NS5A 2209-2248 amino acid substitutions affect serum 2,5AS activities

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Mx proteins: mediators of innate resistance to RNA viruses.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Serological responses to infection with three different types of hepatitis C virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Interferon-alpha therapy in HCV hepatitis: HLA phenotype and cirrhosis are independent predictors of clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

The effect of HLA alleles on response to interferon therapy in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

HLA class II genotypes associated with chronic hepatitis C virus infection and response to alpha-interferon treatment in Poland

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Immunohistochemical analysis of hepatic interferon alpha-beta receptor level: relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Expression of interferon-alpha receptor mRNA in the liver in chronic liver diseases associated with hepatitis C virus: relation to effectiveness of interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Relationship between the intrahepatic expression of interferon-alpha receptor mRNA and the histological progress of hepatitis C virus-associated chronic liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Inducible nitric oxide synthase: what difference does it make?

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Hepatic expression of inducible nitric oxide synthase transcripts in chronic hepatitis C virus infection: relation to hepatic viral load and liver injury

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

STAT activation by epidermal growth factor (EGF) and amphiregulin. Requirement for the EGF receptor kinase but not for tyrosine phosphorylation sites or JAK1.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Cytokine therapeutics: lessons from interferon alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Functionally distinct T-cell epitopes within the hepatitis C virus non-structural 3 protein

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Pathogenesis of hepatocellular damage in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

The biology of interferon-alpha and the clinical significance of anti-interferon antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2901329-0

7 January 2021

10.1016/S1286-4579(00)01329-0

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11137047